Age-related changes in hepatic drug-oxidizing activity using trimethadione as a probe drug in human

Hepatology Research

Volumn 12, Issue 2, 1998, Pages 85-92

  Nakamura, Hirofumi ^a   Tanaka, Einosuke ^a   Ishikawa, Akio ^a   Fukao, Katashi ^a   Tsuji, Katsuhisa ^a   Ohkawa, Haruo ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Cytochrome P 450 isozyme; Developing human beings; Hepatic drug oxidizing activity; Life span; Probe drug; Trimethadione

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450; DIMETHADIONE; MALEIMIDE; TRIMETHADIONE;

ADOLESCENT; ADULT; AGE; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANUS FISTULA; APPENDICITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHILD; CHOLANGITIS; CHOLECYSTITIS; CHOLELITHIASIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG OXIDATION; FEMALE; HUMAN; INFANT; INGUINAL HERNIA; LIFESPAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; NEWBORN; ORAL DRUG ADMINISTRATION; PHIMOSIS; PRIORITY JOURNAL;

EID: 0031692259     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1386-6346(98)00025-4     Document Type: Article

References (27)

1. Kearns G.L., Reed M.D. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet. 17(Suppl 1):1989;29-67.
2. Tanaka E., Ishikawa A., Ono A., Okamura T., Kobayashi S., Yasuhara H., Misawa S. Trimethadione tolerance test for evaluation of functional reserve of the liver in patients with liver cirrhosis and esophageal varices. J Pharm Dyn. 9:1986;297-302.
3. Tanaka E., Ishikawa A., Ono A., Okamura T., Misawa S. Trimethadione metabolism in patients with normal liver and in patients with chronic liver disease. J Pharm Dyn. 10:1987;499-502.
4. Tanaka E., Ishikawa A., Fukao K., Tsuji K., Osada A., Yamamoto Y., Adachi S., Takase Y., Abei M., Iwasaki Y. Trimethadione tolerance test for one-point estimation of the severity of liver damage in cirrhotic patients. Int J Clin Pharmacol Ther Toxicol. 29:1991;333-336.
5. Tanaka E., Ishikawa A., Etoh H., Misawa S., Fukao K., Iwasaki Y. The impact of liver cirrhosis and cholelithiasis on Phase I and II reactions using antipyrine and trimethadione as a model substrate. Jpn J Clin Pharmacol Ther. 22:1991;635-639.
6. Abei M., Tanaka E., Tanaka N., Matsuzaki Y., Ikegami T., Ishikawa T., Osuga T. Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity. J Gastroenterol. 30:1995;478-484.
7. Tanaka E., Ishikawa A., Abei M., Kobayashi S. Trimethadione metabolism as a probe drug to estimate hepatic oxidizing capacity in human. Comp Biochem Physiol. 115:1995;211-216.
8. Nakamura M., Tanaka E., Misawa S., Shimada T., Imaoka S., Funae Y. Trimethadione metabolism, a useful indicator for assessing hepatic drug-oxidizing capacity. Biochem Pharmacol. 47:1994;247-251.
9. Kurata N., Nishimura Y., Inaba T., Fischer N., Iwase M., Yasuhara H. Estimation of the human hepatic microsomal cytochrome P-450 species responsible to the trimethadione metabolism. Jpn J Pharmacol. 73:1997;115.
10. Kobayashi S., Tanaka E., Oguchi K., Yoshida T., Kuroiwa Y., Yasuhara H. A method for estimation of hepatic drug-metabolizing capacity: determination of concentration of trimethadione and its metabolite in human serum. J Pharm Dyn. 7:1982;329-335.
11. Tanaka E., Kobayashi S., Nakamura K., Uchida E., Yasuhara H. Simplified approach for determination of hepatic drug-oxidizing capacity using trimethadione metabolism as an indicator. Biopharm Drug Disp. 10:1989;617-620.
12. Tanaka E., Ishikawa A., Ono A., Okamura T., Misawa S. Age-related changes in trimethadione oxidizing capacity. Br J Clin Pharmacol. 23:1987;355-357.
13. Rowland M, Tozer TN. Age and weight. In: Rowland M, Tozer TN, editors. Clinical Pharmacokinetics: Concepts and Applications. Baltimore: Williams and Wilkins, 1995:230-247.
14. Tanaka E., Misawa S. Simultaneous determination of serum trimethadione and its metabolite by gas chromatography. J Chromatogr Biomed Appl. 413:1987;376-378.
15. Ishikawa A., Fukao K., Tsuji K., Osada A., Yamamoto Y., Ohtsuka M., Tanaka E. Trimethadione tolerance tests for the assessment of feasible size of hepatic resection in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 8:1993;426-432.
16. Boreus L.O. The role of therapeutic drug monitoring in children. Clin Pharmacokinet. 17(Suppl 1):1989;4-12.
17. Evans W.E., Relling M.V., de Graaf S., Rodman J.H., Pieper J.A., Christensen M.L., Crom W.R. Hepatic drug clearance in children: studies with indocyanine green as a model substrate. J Pharm Sci. 78:1986;452-456.
18. Morselli P.L. Clinical pharmacology of the perinatal period and early infancy. Clin Pharmacokinet. 17(Suppl 1):1989;13-28.
19. Crom W.R. Pharmacokinetics in the child. Environ Health Perspect. 102(Suppl 11):1994;111-118.
20. Milsap R.L., Jusko W.J. Pharmacokinetics in the infant. Environ Health Perspect. 102(Suppl 11):1994;107-110.
21. Ono S, Hatanaka T, Miyazawa S, Tsutsumi, Aoyama T, Gonzalez FJ, Satoh T. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996;26:1155-1166.
22. Kearns G.L., Reed M.D. Clinical pharmacokinetics in infants and children. Clin Pharmacokinet. 17(Suppl 1):1989;29-67.
23. Weinberger M., Hendeles L., Ahrens R. Clinical pharmacology of drugs used for asthma. Pediatr Clin North Am. 28:1981;47-75.
24. Done A.K., Cohen S.N., Strebel L. Pediatric clinical pharmacology and the 'therapeutic orphan'. Annu Rev Pharmacol Toxicol. 17:1977;561-573.
25. Hakkola J, Tanaka E, Pelkonen O. Developmental expression of cytochrome P450 enzymes in the human liver. Pharmacol Toxicol 1998, in press.
26. Ogiu N., Nakamura Y., Ijiri I., Hiraiwa K., Ogiu T. A statistical analysis of the internal organ weights of normal Japanese people. Health Phys. 72:1997;368-383.
27. Morgan D.J., McLean A.J. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. Clin Pharmacokinet. 29:1995;370-391.